RYTM News and Press, Rhythm Pharmaceuticals Inc. From 08/05/21

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...

Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...

Rhythm Pharmaceuticals (RYTM -18.3%) has lost more than a tenth in morning hours after the company’s revenue for Q2 2021 lagged analyst estimates on Tuesday. In addition, after the close, the company announced five new mid-stage and late-stage clinical studies for setmelanotide targeti...

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2021 Results Earnings Conference Call August 3, 2021, 08:00 AM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Murray Stewart - Chief Medical ...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals (NASDAQ:RYTM): Q2 GAAP EPS of -$0.70 in-line. Revenue of $0.27M misses by $0.28M. Press Release For further details see: Rhythm Pharmaceuticals EPS in-line, misses on revenue

-- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies -- -- Setmelanotide selected for evaluation as a “Highly Specialised Technology” by Great Britain’s Na...

-- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities -- -- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmela...

-- Pamela Cramer appointed Chief Human Resources Officer -- -- Linda Shapiro Manning, M.D., Ph.D., appointed Senior Vice President, Clinical -- BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical compa...

BOSTON, July 28, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced a collaborative research agreement with the Clinical...